PROTECT 340B Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The PROTECT 340B Act of 2023 is a bill introduced in the 118th Congress aimed at addressing issues related to the 340B Drug Pricing Program, which allows certain healthcare providers to purchase outpatient drugs at reduced prices. The bill was referred to the House Subcommittee on Health but did not advance further and is currently classified as failed or expired. No official summary or full text is available to provide detailed provisions or specific policy changes proposed in the bill.
The PROTECT 340B Act of 2023 sought to amend aspects of the 340B Drug Pricing Program but did not progress beyond subcommittee referral and has expired without enactment.
- The bill is related to the 340B Drug Pricing Program, a federal program that helps eligible healthcare providers access discounted outpatient drugs.
- It was introduced in the House of Representatives during the 118th Congress and referred to the Subcommittee on Health on December 17, 2024.
- The bill did not advance beyond the subcommittee stage and is currently marked as failed or expired.
['Eligible healthcare providers participating in the 340B Drug Pricing Program', 'Patients receiving outpatient drugs from these providers', 'Potentially, healthcare organizations involved in drug purchasing and pricing']
['Lack of available full text and official summary limits understanding of specific policy changes and implementation requirements.', 'Without detailed provisions, it is unclear what oversight or enforcement mechanisms were proposed.', "The bill's failure to advance may reflect challenges in legislative support or competing priorities."]
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. The 340B program has been subject to ongoing legislative and regulatory scrutiny regarding drug pricing and program integrity. The bill's failure to progress suggests it did not gain sufficient traction within the legislative process during this session.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential changes to the 340B program could affect drug pricing dynamics and healthcare provider purchasing behavior if enacted.', 'Failure of the bill to pass may maintain the status quo, impacting ongoing debates about drug pricing and program oversight.']
Transparency is limited due to the absence of the bill's full text and official summary, which restricts detailed public and expert scrutiny. The bill's status as failed or expired indicates no legislative outcome, but monitoring similar future proposals is advisable given the ongoing policy interest in the 340B program.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.